Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open- Monitoring Clear all
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

NCT05514509
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed No phase listed Observational Results available

Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

NCT00262314
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Time-in-range Using Continuous Glucose Monitoring Management of Gestational Diabetes Mellitus

NCT04605497
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring (CGM), Self-Capillary Blood Glucose Monitoring (SCBG)
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

NCT04871815
View directory record Official record
Conditions
Long COVID
Interventions
sodium pyruvate nasal spray
Drug
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Phase 4 Interventional

Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension

NCT00235001
View directory record Official record
Conditions
Hypertension
Interventions
trandolapril/verapamil
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2008 · Synced Oct 22, 2026, 6:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NCT00577772
View directory record Official record
Conditions
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions
Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
Drug · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

NCT02710890
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loxahatchee Groves, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 22, 2026, 6:24 PM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

NCT00909558
View directory record Official record
Conditions
Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
Interventions
Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Biological
Lead sponsor
Envita Medical Center, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 22, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

NCT00617058
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, healthy lifestyle intervention
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NIRS Guidance Trail in Children's Heart Surgery

NCT02157597
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
NIRS based management, Control
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 6 Months
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT07287397
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Mechanisms of Mindfulness Meditation and Self-Hypnosis for Pain in Older Adults With Chronic Pain

NCT06957743
View directory record Official record
Conditions
Chronic Pain
Interventions
Mindfulness Meditation, Therapeutic Hypnosis, Story Listening
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Not yet recruiting Phase 2 Interventional

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181
View directory record Official record
Conditions
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Jonathan Santoro
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

NCT03531814
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions
Medication Event Monitoring System (MEMS^TM), Questionnaires
Behavioral · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Phase 3 Interventional

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

NCT02705053
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 22, 2026, 6:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

NCT06689696
View directory record Official record
Conditions
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions
miLens system
Device
Lead sponsor
Smartlens, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fullerton, California • Petaluma, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Active, not recruiting Not applicable Interventional

Accelerated High-Dose tDCS for Depression

NCT07226011
View directory record Official record
Conditions
Major Depression, Major Depression Disorders
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed No phase listed Observational

Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers

NCT03419871
View directory record Official record
Conditions
Sleep Disorder
Interventions
Monitoring Sleep, stress biomarkers
Other
Lead sponsor
Yale University
Other
Eligibility
12 Months to 15 Months
Enrollment
100 participants
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

NCT04142177
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
Other · Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

NCT07013435
View directory record Official record
Conditions
Lymphoma
Interventions
Health Education Program, SMART3RP-Lymphoma
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Placebo Impacts Sleep and Pain Modulation in Chronic Pain

NCT06225817
View directory record Official record
Conditions
Chronic Pain, Headache
Interventions
Open-label placebo pills
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Internet Delivered Parent Child Interaction Therapy

NCT05725525
View directory record Official record
Conditions
Disruptive Behavior
Interventions
Remote PCIT augmented with wearable devices
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 22, 2026, 6:24 PM EDT